Drugs / SM-030
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06454747 | Jun 2024 → Apr 2025 overdue | hyperpigmentation of the skin | DermBiont, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SM-030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06454747 ↗ |
| Route | Topical | “Topical application to face twice daily for 12 weeks.” NCT06454747 ↗ |